Clinical Trials Logo

Alopecia Areata clinical trials

View clinical trials related to Alopecia Areata.

Filter by:

NCT ID: NCT05587257 Not yet recruiting - Alopecia Areata Clinical Trials

Role of Minoxidil in Alopecia Areata Transepidermal Drug Delivery of Minoxidil Via Either Fractional Carbon Dioxide Laser or Microneedling Versus Its Topical Nanoparticles Preparation for Treatment of Alopecia Areata

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

- Compare the clinical efficacy, and safety of transepidermal drug delivery of fractional CO2 laser versus microneedling followed by minoxidil 5% application for the treatment of alopecia areata. - Evaluate the efficacy, and safety of minoxidil nanoparticles as a topical treatment of alopecia areata.

NCT ID: NCT05556265 Terminated - Alopecia Areata Clinical Trials

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

Start date: November 8, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of Deucravacitinib versus placebo at Week 24 and safety and tolerability of Deucravacitinib versus placebo in adults with Alopecia Areata.

NCT ID: NCT05551793 Recruiting - Alopecia Areata Clinical Trials

Regeneron AA Multicenter (Dupilumab)

Start date: April 10, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers through Week 48. AA subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥ 200 and/or have personal and/or familial history of atopy. Subjects will be randomized (2:1) to either receive weekly dupilumab or placebo for 48 weeks, with all subjects completing participation through Week 48 receiving an additional 48 weeks of dupilumab (through Week 96).

NCT ID: NCT05549934 Recruiting - Clinical trials for Cicatricial Alopecia

Ritlecitinib for Cicatricial Alopecia

Start date: December 15, 2022
Phase: Phase 2
Study type: Interventional

Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known as cicatricial alopecia (CA), in which hair follicles are irreversibly destroyed. CA leads to scarred areas, most commonly on the scalp, that cannot re-grow hair. Despite being a long-term condition, that often has significant impact on patients' well-being, available effective treatments for these diseases are lacking. In addition, the molecular abnormalities causing CA are largely unknown. The research team will be administering a new investigational drug (a JAK3/TEC inhibitor), ritlecitinib, which has shown statistically significant improvement in scalp hair loss for AA patients in a proof of concept and phase 2b/3 studies (B7981015 AA study). This is an open-label clinical trial. CA patients will be asked to provide small samples of skin and blood throughout the treatment period, to find out how they respond to the drug, and to attempt to better understand these diseases.

NCT ID: NCT05522556 Available - Alopecia Areata Clinical Trials

Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)

Start date: n/a
Phase:
Study type: Expanded Access

Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.

NCT ID: NCT05502952 Recruiting - Alopecia Areata Clinical Trials

Combined Microneedling and Topical Pentoxifylline Vesrus Intalesional Pentoxifylline in Treatment of Alopecia Areata: Intra-indiviual Comparative Study

Start date: July 27, 2022
Phase: N/A
Study type: Interventional

Alopecia areata (AA) is a common autoimmune disease that targets hair follicles with a prevalence of approximately 0.1% and a lifetime incidence of approximately 1.7%. AA is the third most prevalent nonscarring hair loss disease. Pentoxifylline (PTX) is a non-selective inhibitor of phosphodiesterases, which moderates the intracellular levels of cyclic adenosine monophosphate and cyclic guanosine monophosphate by decreasing their hydrolysis and augmenting cyclic nucleotide-dependent signal transduction which leads to a wide spectrum of effects on the inflammation. PTX has anti inflammatory effects by inhibiting the pro-inflammatory cytokines (eg, IL-1, IL-6, and IL-8).Intralesional therapy has a number of advantages over topical therapy, including a faster and longer duration of action, penetration that is deeper than topical therapy, removal of the need for long-term topical medication, and improved patient compliance.The effect of microneedling for treatment of AA is supposed to stimulate the dermal papilla and stem cells by mechanical trauma and increasing the blood supply to the hair follicles.

NCT ID: NCT05496426 Not yet recruiting - Alopecia Areata Clinical Trials

A Study of KL130008 in Adults With Severe Alopecia Areata

Start date: October 31, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess KL130008 is safe and effective in adults with severe alopecia areata

NCT ID: NCT05485571 Not yet recruiting - Alopecia Areata Clinical Trials

Efficacy of Combined Microneedling With Methotrexate in Treatment of Alopecia Areata

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

Alopecia areata (AA) is a common cause of non-cicatricial hair loss It is the second-most frequent non-scarring alopecia, after androgenic alopecia. The prevalence of the disease is 0.2% in the general population with higher prevelance in younger (21-40 years of age) patients but no significant difference in incidence between males and females. Several treatment options such as corticosteroids, anthralin, topical minoxidil, immunotherapy, and systemic therapy are commonly used with varying response . Unfortunately the traditional treatment options are frequently disappointing Available treatments may induce regrowth but do not modify the disease course . Methotrexate (MTX) is a folic acid analog that binds to the dihydrofolate reductase enzyme, blocking the formation of tetrahydrofolate and so inhibits purine and pyrimidine metabolism and consequently nucleic acid synthesis. It acts as an immunosuppressant used in the treatment of several skin diseases Systemic MTX has been used in the treatment of AA, with satisfactory results. Microneedling is a minimally invasive procedure that utilizes multiple fine needles to create micropunctures in the skin.The act of creating these two to four cell-wide puncture holes triggers neovascularization, release of growth factors, and stimulates the expression of Wnt proteins. it has specifically been demonstrated to increase hair regrowth in alopecia via the release of platelet-derived growth factor, epidermal growth factors and activation of the hair bulge, all of which are triggered by the wound healing response .Increased expression of Wnt proteins, namely Wnt3a and Wnt10b, is also evident following microneedling. These particular proteins have been demonstrated to stimulate dermal papillae stem cells and hair growth.

NCT ID: NCT05484973 Not yet recruiting - Breast Cancer Clinical Trials

Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss

Start date: March 31, 2024
Phase: N/A
Study type: Interventional

The purpose of this prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer. Additionally, the purpose is also to assess the safety, tolerability and compliance, quality of life, and satisfaction with hair preservation after CT treatment.

NCT ID: NCT05470413 Active, not recruiting - Alopecia Areata Clinical Trials

Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

Start date: April 18, 2022
Phase: Phase 3
Study type: Interventional

This is a multi-central, double-blind, randomized, parallel, placebo-controlled phase 3 study in adult subjects with severe alopecia areata (SALT≥50%). Approximately 330 adult patients will be enrolled into the study. Efficacy and safety of two doses of SHR0302 will be compared to placebo.